ImgPhones

احصل على تخفيض١٥٪ على علي مستلزمات الصيدلية

حمل تطبيق فيزيتا الآن ادخل بروموكود PH15 واحصل على أوسع تغطية، تتبع فوري لطلباتك، وتجربة سلسة ومريحة - كل ذلك في تطبيق واحد.

حمل التطبيق الآن

AppleStoreImgGoogleStoreImgAppGalleryStoreImg

Vecovartec 20 mg - 21 F.C. Tablet

Box
هذه الصفحة قد لا تغطي جميع المعلومات المذكورة في نشرة الشركة المصنعة المرفقة

الوصف الطبي

Angiotensin II receptor blocker used in the treatment of chronic hypertension, acute coronary syndromes and proteinuric chronic kidney disease.

الدلالة و الاستخدام

-Chronic hypertension: Oral: 20 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed up to 40 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week. -Non-ST-elevation acute coronary syndrome: Oral: Initial: 20 mg once daily; increase dose as tolerated up to 40 mg/day. -ST-elevation myocardial infarction: Oral: Initial: 20 mg once daily; increase dose as tolerated up to 40 mg/day. -Proteinuric chronic kidney disease: Oral: Initial: 20 mg once daily; can be increased to 40 mg once daily based on blood pressure response and tolerability. Target to an appropriate blood pressure goal and a proteinuria goal of <1 g/day. -Pediatric dosing: -Hypertension: Oral: Children 1 to 5 years and ≥5 kg: Limited data available: Initial: 0.3 mg/kg/dose once daily; if initial response inadequate after 2 weeks, dose may be increased to 0.6 mg/kg/dose once daily. While in case of children and adolescents 6 to 16 years: If the patient weight is 20 to <35 kg: 10 mg once daily; if initial response inadequate after 2 weeks, dose may be increased; maximum daily dose: 20 mg/day, if the patient weight is ≥35 kg: 20 mg once daily; if initial response inadequate after 2 weeks, dose may be increased; maximum daily dose: 40 mg/day. While in case of adolescents >16 years: Initial: 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks.

المكونات النشطة

Olmesartan

دكاترة مرشحين

لم يتم العثور على دكاترة مرشحين

الجرعة و طريقة الاستعمال

Administer with or without food.

الاّثار الجانبية

Dizziness, headache, hyperglycemia, hypertriglyceridemia, diarrhea, hematuria, back pain, increased creatine phosphokinase, bronchitis, flu-like symptoms, pharyngitis, rhinitis, sinusitis.

نصائح احترازية

-Should not be given to patients suffering from hypersensitivity to Olmesartan. -Severe diarrhea with significant weight loss may develop months to years after treatment initiation. -It may cause hyperkalemia. -Hypotension may occur upon initiation in patients who are salt- or volume-depleted. -May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow. -Use with caution in patients with significant aortic/mitral stenosis. -Avoid use in patients with ascites due to cirrhosis. -Use Olmesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. -Olmesartan has not been shown to be effective for hypertension in children <6 years of age. -In Black patients, the BP-lowering effects of ARBs may be less pronounced. -Elderly patients should be adequately hydrated to avoid increasing the risk of drug induced hypotension. -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

التخزين

Store at room temperature.

تفاعلات الأدوية

-Alfuzosin: May enhance the hypotensive effect of blood pressure lowering agents. -Antipsychotic Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents. -Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers. -Duloxetine: blood pressure lowering agents may enhance the hypotensive effect of Duloxetine. -Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. -Levodopa-containing products: blood pressure lowering agents may enhance the hypotensive effect of Levodopa-Containing Products. -Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium. -Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. -Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. -Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. -Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. -Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. -Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.

الحمل والرضاعة

-Drugs that act on the renin-angiotensin system can cause injury to the developing fetus. The use of angiotensin II receptor blockers is generally not recommended to treat chronic hypertension in pregnant women -It is not known if Olmesartan is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, it is recommended that the decision whether to discontinue breastfeeding or to discontinue the drug, should consider the importance of treatment to the mother.

صناعة

MARCYRL

ملاحظة

أظهر المزيد

عنوان التوصيل

إضافة عنوان

هل تريد مسح العنوان المسجل ؟

إلغاء
مسح